TO THE EDITOR
Inhibition of the BCR-ABL protein kinase with imatinib (Glivec, Gleevec) has been shown to be a novel therapeutic option in Philadelphia chromosome-positive chronic myeloid leukemia (CML), with remarkable response rates in chronic phase. 1 In accelerated phase and blast crisis, however, imatinib results only in a limited increase of overall survival and cytogenetic response rates. 2 In imatinib-treated patients who reach a complete cytogenetic remission (CCR), mobilization and collection of CD34 þ cells may represent an additional therapeutic option, as in vivo purging may be achieved when therapy with imatinib is continued during stem cell collection. These stem cells could be used for autologous blood stem cell transplantation (ASCT) in patients with relapse of leukemia. In fact, Hui et al 3 recently showed successful peripheral blood stem cell mobilization in patients who reached CCR under imatinib. Here, we describe the case of a 59-year-old female blast crisis patient who was successfully treated by ASCT of stem cells collected in CCR.
Prior to CML, this patient was diagnosed with breast cancer and was treated by surgery and repetitive cycles of systemic chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil). CML in first chronic phase was diagnosed in 1996. After harvesting stem cells (14.1 Â 10 6 CD34 þ cells/kg/BW), therapy was started with hydroxyurea and after 2 weeks changed to interferon-a. In August 2000, the therapy was changed to imatinib (400 mg) because of the loss of cytogenetic response and interferon-a-related side effects. In September 2001, the patient developed pancytopenia and bone marrow analysis revealed first lymphatic blast crisis and clonal evolution (ISCN -karyotype: 46,XX[4]/47,XX,t(9;22)(q34;q11), þ 12[2]/51, XX, þ 6, þ 8, þ 10,À9, þ t(?1;9;22)(?::p23;q34;q11), þ 19,À22, þ der(22)t(9;22)(q34;q11) Â 2[18]).
First ASCT was considered, and after one cycle of BEAM (BCNU, etoposide, cytarabine and melphalan) 7.0 Â 10 6 /kg/BW CD34 þ cells were transfused in October 2001. ASCT was well tolerated and hematopoietic regeneration was normal. The patient remained Philadelphia chromosome positive, but without additional cytogenetic abnormalities, and was re-exposed to imatinib (400 mg o.d.).
In 2002, consecutive bone marrow aspirations demonstrated a CCR. We therefore mobilised CD34 þ stem cells with 10 mg/ kg/BW G-CSF daily, while imatinib (400 mg) was continued. Stem cell apheresis yielded 4.9 Â 10 6 /kg/BW CD34 þ cells and 3.9 Â 10 8 /kg/BW mononuclear cells, respectively. The viability of this stem cell product was 89%; however, a CFU-GM assay showed no proliferative activity. In December 2002, the patient progressed again into second blast crisis (hemoglobin:8.2 g/dl, WBC: 4.9 Â 10 3 /ml and platelets: 7 Â 10 3 /ml) and myeloid blast crisis was confirmed. Cytogenetic analysis revealed a complex aberrant karyotype with multiple amplifications of the Philadelphia chromosome and trisomy 12: 47,XX,t(9;22)(q34;q11), þ 12[11]/48,XX,t(9;22)(q34;q11), þ 12, þ der(22)t(9;22)(q34;q11)[10]/49,XX,t(9;22)(q34;q11), þ 12, þ der(22) t(9;22)(q34;q11) Â 2[3]/50,XX,t(9;22)(q34;q11), þ 12, þ der(22) t(9;22)(q34;q11) Â 3 [1] . Fluorescence in situ hybridization (FISH) analysis with the commercially available BCR-ABL-ES probe (Vysis, Downers Grave, IL, USA) showed in 100 analyzed interphase nuclei a single BCR-ABL fusion signal in 7%, two BCR-ABL fusion signals in 91% and three BCR-ABL fusion signals in 1%, while only one nucleus was normal.
Due to age, the intensive pretreatment and lack of a compatible unrelated donor allogeneic peripheral stem cell transplantation was not possible. We therefore decided to perform second ASCT with the stem cells collected in CCR. The patient was informed about the risks of this intervention and gave her written informed consent.
Imatinib was discontinued 31 days before ASCT. Myeloablative conditioning therapy (TBI (12 Gy administered in six fractions from day -6 until day -4) and cyclophosphamide 2 Â 60/mg/kg/day (days -3 and -2)) and stem cell transplantation (4.9 Â 10 6 /kg/BW) were well tolerated, and the patient did not develop any severe toxicity.
FISH analysis of the stem cell preparation given to the patient resulted in weak BCR-ABL positivity (3.5% of 200 analyzed interphase nuclei were Philadelphia positive). Hematologic reconstitution was delayed and a WBC above 1.000/ml was only achieved at day 32, with the concomitant application of G-CSF. Likewise, platelets remained below 50.000/ml throughout the entire observation period. A bone marrow aspirate taken at day 51 excluded relapse of leukaemia, and flow cytometry of the peripheral blood at day 56 revealed 0.4/ml CD34 þ cells (0.01% of all WBC). At days 14, 28, 42, 51, 76, 106 and 147 at least 200 interphase nuclei were evaluated, and solely on day 14 5.7% BCR-ABL-positive cells were detected by FISH. All consecutive analyses remained BCR-ABL negative. PCR analysis was performed on days 42 and 141 as indicated in Figure 1 . Here, the bcr/abl fusion transcript was detectable by nested PCR, but not in the first-round PCR, indicating a drastic decrease of bcr/abl copy numbers.
In the era of imatinib, CCR in chronic phase has become a more realistic therapeutical goal and therefore may lead to a combined use of imatinib and ASCT in relapsed patients. Additionally, concomitant therapy with imatinib and stem cell stimulation with G-CSF in CCR may lead to an intensified clearance of BCR-ABL-positive cells by subjecting dormant bcr/ abl-positive stem cells to the inhibitory and apoptotic effect of imatinib. Several factors might have contributed to the delayed and incomplete hematologic reconstitution seen in this patient. First, the toxicity of previous chemotherapy (CMF) because of bilateral breast cancer as well as the conditioning therapy (BEAM) given at the first autologous SCT have to be considered. Second, the relatively long history of CML resulting in myelofibrosis could play a role.
In summary, we observed the occurrence of tolerable toxicity in this approach, but engraftment of CD34 þ cells in an autotransplant setting in second blast crisis. Further, our patient remained in CCR during a follow-up of 5 months with an acceptable molecular response as detected by conventional PCR. We therefore recommend to pursue a prospective clinical trial to further evaluate the overall survival of patients after ASCT of CD34 þ stem cells harvested in CCR. 
